Trial Outcomes & Findings for Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (NCT NCT02782546)

Last Updated: 2026-06-01

Results Overview

-LFS is defined as the time from achievement of complete remission (CR) to the time of relapse, death in remission, or last follow-up.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE2

Target enrollment

60 participants

Primary outcome timeframe

1 year post transplantation

Results posted on

2026-06-01

Participant Flow

Participant milestones

Participant milestones
Measure	Recipient * Standard of care reduced conditioning regimen on Day -1 * Graft cell infusion on Day 0 * Post-transplant cyclophosphamide on Days +3 and +4 * GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD * G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines * The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes. * ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses	Donor * Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines. * Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection. * On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft.
Overall Study STARTED	30	30
Overall Study COMPLETED	29	29
Overall Study NOT COMPLETED	1	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Recipient * Standard of care reduced conditioning regimen on Day -1 * Graft cell infusion on Day 0 * Post-transplant cyclophosphamide on Days +3 and +4 * GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD * G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines * The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes. * ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses	Donor * Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines. * Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection. * On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft.
Overall Study Did not collect enough NK cells from donor	1	0
Overall Study Did not produce enough NK cells	0	1

Baseline Characteristics

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Recipient n=30 Participants * Standard of care reduced conditioning regimen on Day -1 * Graft cell infusion on Day 0 * Post-transplant cyclophosphamide on Days +3 and +4 * GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD * G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines * The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes. * ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses	Donor n=30 Participants * Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines. * Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection. Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines. -On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft.	Total n=60 Participants Total of all reporting groups
Age, Continuous	57 years n=24 Participants	39.9 years n=24 Participants	48.5 years n=48 Participants
Sex: Female, Male Female	13 Participants n=24 Participants	16 Participants n=24 Participants	29 Participants n=48 Participants
Sex: Female, Male Male	17 Participants n=24 Participants	14 Participants n=24 Participants	31 Participants n=48 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=24 Participants	1 Participants n=24 Participants	1 Participants n=48 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	30 Participants n=24 Participants	27 Participants n=24 Participants	57 Participants n=48 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=24 Participants	2 Participants n=24 Participants	2 Participants n=48 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=24 Participants	0 Participants n=24 Participants	0 Participants n=48 Participants
Race (NIH/OMB) Asian	0 Participants n=24 Participants	0 Participants n=24 Participants	0 Participants n=48 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=24 Participants	0 Participants n=24 Participants	0 Participants n=48 Participants
Race (NIH/OMB) Black or African American	2 Participants n=24 Participants	2 Participants n=24 Participants	4 Participants n=48 Participants
Race (NIH/OMB) White	28 Participants n=24 Participants	27 Participants n=24 Participants	55 Participants n=48 Participants
Race (NIH/OMB) More than one race	0 Participants n=24 Participants	0 Participants n=24 Participants	0 Participants n=48 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=24 Participants	1 Participants n=24 Participants	1 Participants n=48 Participants
Region of Enrollment United States	30 participants n=24 Participants	30 participants n=24 Participants	60 participants n=48 Participants

PRIMARY outcome

Timeframe: 1 year post transplantation

Population: Evaluable recipients only include those who achieved CR.

-LFS is defined as the time from achievement of complete remission (CR) to the time of relapse, death in remission, or last follow-up.

Outcome measures

Outcome measures
Measure	Recipient n=18 Participants * Standard of care reduced conditioning regimen on Day -1 * Graft cell infusion on Day 0 * Post-transplant cyclophosphamide on Days +3 and +4 * GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD * G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines * The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes. * ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses
Kaplan-Meier Estimate of Leukemia-free Survival Rate (LFS)	16.67 percentage of participants-Kaplan Meier Interval 5.93 to 46.82

SECONDARY outcome

Timeframe: 3 months post transplantation

Population: Evaluable recipients only include those who achieved CR.

-LFS is defined as the time from achievement of CR to the time of relapse, death in remission, or last follow-up.

Outcome measures

Outcome measures
Measure	Recipient n=18 Participants * Standard of care reduced conditioning regimen on Day -1 * Graft cell infusion on Day 0 * Post-transplant cyclophosphamide on Days +3 and +4 * GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD * G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines * The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes. * ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses
Kaplan-Meier Estimate of Leukemia-free Survival Rate (LFS)	61.11 percentage of participants-Kaplan Meier Interval 42.27 to 88.34

SECONDARY outcome

Timeframe: 1 year post transplantation

-OS is defined as the time from the date of Day 0 until death from any cause.

Outcome measures

Outcome measures
Measure	Recipient n=29 Participants * Standard of care reduced conditioning regimen on Day -1 * Graft cell infusion on Day 0 * Post-transplant cyclophosphamide on Days +3 and +4 * GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD * G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines * The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes. * ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses
Kaplan-Meier Estimate of Overall Survival (OS)	31.034 percentage of participants-Kaplan Meier Interval 18.04 to 53.39

SECONDARY outcome

Timeframe: Day 28 post transplantation

Population: Evaluable recipients only include those who achieved CR.

-CR: Morphologically leukemia free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no blasts with Auer rods, no evidence of extramedullary leukemia) and absolute neutrophil count ≥1000 /μL and platelets ≥100,000 /μL. Patient must be independent of transfusions.

Outcome measures

Outcome measures
Measure	Recipient n=13 Participants * Standard of care reduced conditioning regimen on Day -1 * Graft cell infusion on Day 0 * Post-transplant cyclophosphamide on Days +3 and +4 * GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD * G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines * The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes. * ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses
Incidence of Relapse in Recipients Who Are Found to be CR (Complete Remission)	8 Participants

SECONDARY outcome

Timeframe: Day 28 post transplantation

CR: Morphologically leukemia free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no blasts with Auer rods, no evidence of extramedullary leukemia) and absolute neutrophil count ≥1000 /μL and platelets ≥100,000 /μL. Patient must be independent of transfusions

Outcome measures

Outcome measures
Measure	Recipient n=29 Participants * Standard of care reduced conditioning regimen on Day -1 * Graft cell infusion on Day 0 * Post-transplant cyclophosphamide on Days +3 and +4 * GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD * G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines * The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes. * ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses
Complete Remission (CR) Rate	13 Participants

Adverse Events

Recipient

Serious events: 10 serious events

Other events: 29 other events

Deaths: 27 deaths

Donor

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Other adverse events

Additional Information

Amanda Cashen, M.D.

Washington University School of Medicine

Phone: 314-454-8323

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Other adverse events
Measure	Recipient n=29 participants at risk * Standard of care reduced conditioning regimen on Day -1 * Graft cell infusion on Day 0 * Post-transplant cyclophosphamide on Days +3 and +4 * GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD * G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines * The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes. * ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses	Donor * Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines. * Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection. * On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft.
Blood and lymphatic system disorders Anemia	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Blood and lymphatic system disorders Febrile neutropenia	17.2% 5/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Cardiac disorders Chest pain - cardiac	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Cardiac disorders Heart Failure	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Cardiac disorders Sinus bradycardia	10.3% 3/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Cardiac disorders Sinus tachycardia	6.9% 2/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Cardiac disorders Tachycardia	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Cardiac disorders Ventricular tachycardia	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Ear and labyrinth disorders Hearing impaired	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Endocrine disorders Hypothyroidism	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Eye disorders Dry eye	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Abdominal distension	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Abdominal pain	34.5% 10/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Anal pain	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Ascites	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Bloating	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Colitis	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Constipation	10.3% 3/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Diarrhea	34.5% 10/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Dry mouth	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Dyspepsia	10.3% 3/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Dysphagia	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Esophagitis	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Fecal incontinence	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Gastroesophageal reflux disease	10.3% 3/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Gastrointestinal pain	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Hemorrhoids	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Ileus	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Mucositis oral	37.9% 11/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Nausea	62.1% 18/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Oral hemorrhage	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Oral pain	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Oral pain - tongue	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Rectal pain	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Stomach pain	6.9% 2/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Thrush	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
Gastrointestinal disorders Vomiting	65.5% 19/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
General disorders Catheter site redness	3.4% 1/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
General disorders Chills	17.2% 5/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.
General disorders Edema limbs	20.7% 6/29 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.	— 0/0 • - Adverse events for recipients were collected from the CIML NK cell infusion until 100 days after CIML NK cell infusion and 30 days after last injection of ALT-803. Adverse events of interest were collected until the last scheduled subject contact at 48 months after the last injection of ALT-803. - All cause mortality was collected from the start of treatment through completion of follow-up (up to 48 months) -Adverse events were not collected on donors Adverse events of interest are graft failure, any grade acute graft versus host disease, and extensive chronic graft versus host disease.